For North America: Amy Martin Vogt at firstname.lastname@example.org or 202-745-5052.
For Europe/Asia: Bénédicte Clement at email@example.com or +33 6 10 25 38 96
Nov 20-22: scientific research community gathers to review new and better treatmentS across the alzheimer’s disease spectrum
Philadelphia to Host 7th Annual International Conference on Clinical Trials for AD
||The 7th Annual International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) will gather more than 600 global researchers to review the most important and promising developments in the field. This year’s meeting will feature over 50 oral presentations and 70 poster sessions on Phase 2 and 3 clinical trials, prevention studies, animal models, and more.
A few research highlights include:
- The Collaboration for Alzheimer's Prevention (CAP): Advancing the Evaluation of Alzheimer’s prevention therapies
CAP was established as an umbrella group to promote the use of common tools, share knowledge, and exploit synergies so that data emerging from four trials could inform the entire Alzheimer's research field and expedite the development of more effective treatments. Investigators will provide updates from all four CAP trials: DIAN-TU, API, A4 and the TOMMORROW study. (Thursday, November 20, 9:00 a.m.)
- Resveratrol is Safe and Well-Tolerated and Stabilizes Plasma and CSF A40 Levels in Mild-Moderate Alzheimer’s Disease
R. Scott Turner, MD, PhD, Director, Memory Disorders Program, Georgetown University, Washington, DC will report on a Phase II multi-site study testing the safety and effectiveness of resveratrol, a compound found in red wine and red grapes. To evaluate the effects of resveratrol, the investigators measured the levels in the CSF of different forms of the amyloid protein.
(Thursday, November 20, 11:15 a.m.)
- Amyloid PET Imaging Results from a Study to Evaluate the Impact of Crenezumab on Fibrillar Amyloid in Patients with Mild-to Moderate Alzheimer’s Disease
A group of investigators led by neurologist Stephen Salloway, MD, Director of Neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island and a professor at Brown Medical School, will report the latest findings from two studies of crenezumab, an antibody that targets amyloid. (Thursday, November 20, 12:15 p.m.)
- Development of AVP-923 (Dextromethorphan/Quinidine) for Pseudobulbar Affect (PBA): Results from the Alzheimer’s Disease/Dementia Cohort of PRISM II
Rachelle S. Doody, MD, PhD, Director, Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston, Texas will discuss Phase 2 clinical trials which led to the approval of AVP-923 enrolled patients with multiple neurological conditions (including AD), who also had a diagnosis of PBA. The PRISM study is a 12-week, open label study of the safety, tolerability, and effectiveness of AVP-923 for PBA in patients with stroke, traumatic brain injury, or dementia. The dementia cohort enrolled and completed first and is the subject of this report. The drug significantly reduced PBA symptoms and was well tolerated, further supporting utility in this population. (November 21, 2:45 PM)
Presenters at CTAD will discuss other important developments in the search for new and better treatments for Alzheimer’s disease. The full program is available online at www.ctad-alzheimer.com. Research materials will be posted under the CTAD press tab as embargoes lift at: http://www.ctad.fr/12-press/press.asp. To request embargoed copies of the papers or to schedule interviews with any of the presenters, please contact Amy Martin Vogt at firstname.lastname@example.org or 202-745-5052.
Paul Aisen, MD
Director, Alzheimer’s Disease Cooperative Study, University of California, San Diego
Jacques Touchon, MD, PhD
University Hospital of Montpellier, France
Bruno Vellas, MD, PhD
University Hospital of Toulouse, France
Michael Weiner, MD
University of California, San Francisco
Thursday, November 20 – Saturday, November 22, 2014
Loews Philadelphia Hotel
1200 Market Street
Philadelphia, PA 19107
If you plan to attend, please register for your press pass before November 18, 2014. To register or to schedule embargoed interviews with any of the presenters, please contact Amy Martin Vogt at email@example.com or 202-745-5052.
Since 2008, CTAD has been a conference organized and planned by Alzheimer’s disease (AD) clinical researchers for AD clinical researchers. CTAD embraces the organizing committee mandate to maintain CTAD’s unique role in AD research: To provide a substantive, clinical research-oriented conference and an annual opportunity for the world’s preeminent clinical researchers to engage in both formal and informal exchanges of views. CTAD’s ongoing commitment to providing a relatively intimate forum has resulted in the conference’s reputation of facilitating and fostering international collaboration in AD clinical research matters. More information is available at www.ctad.fr